Cost-effectiveness analysis of dapagliflozin for people with chronic kidney disease in Malaysia
PLOS ONE · 2024
DOI: 10.1371/journal.pone.0296067 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS ONE, 2024. Verfasst von Soo Kun Lim und 1 weiteren Autor:innen. Beteiligte Einrichtung: Renal Division, Department of Medicine, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia. Hauptthemen laut MEDLINE: Cost-Effectiveness Analysis, Renal Insufficiency, Chronic, Benzhydryl Compounds, Glucosides. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: AstraZeneca Malaysia.
Abstract (Originalsprache)
Introduction
Chronic kidney disease (CKD) is a global health concern which results in significant economic burden. Despite this, treatment options are limited. Recently, dapagliflozin has been reported have benefits in people with CKD. This study aimed to evaluate the cost–effectiveness of dapagliflozin as an add-on to standard of care (SoC) in people with CKD in Malaysia.
Methods
A Markov model was adapted to estimate the economic and clinical benefits of dapagliflozin in people with Stage 2 to 5 CKD. The cost-effectiveness was performed based upon data from the Dapagliflozin and Prevention of Adverse Outcomes in Chronic Kidney Disease (DAPA-CKD) trial supplemented with local costs and utility data whenever possible.
Results
In Malaysia, dapagliflozin in combination with SoC was the dominant intervention compared to SoC alone (RM 81,814 versus RM 85,464; USD19,762 vs USD20,644). Adding dapagliflozin to SoC in people with CKD increased life expectancy by 0.46 years and increased quality-adjusted life years (QALY) by 0.41 in comparison with SoC alone (10.01 vs. 9.55 years, 8.76 vs. 8.35 QALYs). This translates to a saving of RM8,894 (USD2,148) with every QALY gained. The benefits were due to the delay in CKD progression, resulting in lower costs of dialysis and renal transplantation. Results were robust to variations in assumptions over disease management costs as well as subgroup of population that would be treated and below the accepted willingness-to-pay thresholds of RM 46,000/QALY.
Conclusion
The use of dapagliflozin was projected to improved life expectancy and quality of life among people with CKD, with a saving RM8,894 (USD2,148) for every quality-adjusted life-year gained and RM7,898 (USD1,908) saving for every life year gained.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Renal Division, Department of Medicine, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia.
- School of Pharmacy, Monash University Malaysia, Subang Jaya, Selangor, Malaysia.
ORCID-Profile: Soo Kun Lim, Shaun Wen Huey Lee
Förderung
- AstraZeneca Malaysia
Zitieren
APA
Lim, S. K., & Lee, S. W. H. (2024). Cost-effectiveness analysis of dapagliflozin for people with chronic kidney disease in Malaysia. PLOS ONE. https://doi.org/10.1371/journal.pone.0296067
Vancouver
Lim SK, Lee SWH. Cost-effectiveness analysis of dapagliflozin for people with chronic kidney disease in Malaysia. PLOS ONE. 2024. doi:10.1371/journal.pone.0296067
BibTeX
@article{Lim2024,
author = {Lim, Soo Kun and Lee, Shaun Wen Huey},
title = {Cost-effectiveness analysis of dapagliflozin for people with chronic kidney disease in Malaysia},
journal = {PLOS ONE},
year = {2024},
doi = {10.1371/journal.pone.0296067}
}
EUVIMED